Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

Luis G. Paz-Ares, Tudor Eliade Ciuleanu, Adam Pluzanski, Jong Seok Lee, Justin F. Gainor, Gregory A. Otterson, Clarisse Audigier-Valette, Neal Ready, Michael Schenker, Helena Linardou, Reyes Bernabe Caro, Mariano Provencio, Bogdan Zurawski, Ki Hyeong Lee, Sang We Kim, Claudia Caserta, Suresh S. Ramalingam, David R. Spigel, Julie R. Brahmer, Martin ReckKenneth J. O'Byrne, Nicolas Girard, Sanjay Popat, Solange Peters, Arteid Memaj, Faith Nathan, Nivedita Aanur, Hossein Borghaei

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Fingerprint

Dive into the research topics of 'Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science